IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites
PR Newswire•20/10/2026•07:55 ET
0
Key Highlights
- ➤IceCure (ICCM) enrolled first two patients at two U.S. ChoICE Study sites
- ➤ChoICE Study targets approximately 400 patients across up to 30 U.S. sites
- ➤Participating sites may also commercially offer ProSense® to eligible non-study patients
- ➤FDA-cleared indication covers low-risk breast cancer patients aged 70 and older
Expert Statements
Eyal Shamir, Chief Executive Officer of IceCure Medical
“Enrolling the first patients marks continued progress in the execution of our post-market strategy for ProSense®. As we continue to expand the ChoICE Study's clinical network, we aim to generate additional real-world evidence while supporting broader clinical adoption and access to minimally invasive cryoablation for eligible patients.”
IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites PR Newswire
CAESAREA, Israel, Oct. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the enrollment of the first two patients at two U.S. clinical sites in its post-marketing study (the "ChoICE Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer.
Get started
Create a free account to read the full story.